Strs Ohio Purchases 10,400 Shares of TransMedics Group, Inc. (NASDAQ:TMDX)

Strs Ohio grew its position in TransMedics Group, Inc. (NASDAQ:TMDX – Get Rating) by 2,080.0% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 10,900 shares of the company’s stock after purchasing an additional 10,400 shares during the quarter. Strs Ohio’s holdings in TransMedics Group were worth $454,000 as of its most recent SEC filing.

A number of other institutional investors also recently modified their holdings of TMDX. FNY Investment Advisers LLC bought a new position in shares of TransMedics Group in the second quarter valued at approximately $31,000. Prospera Financial Services Inc bought a new position in shares of TransMedics Group in the second quarter valued at approximately $69,000. Amalgamated Bank bought a new position in TransMedics Group during the first quarter worth $114,000. Captrust Financial Advisors increased its position in TransMedics Group by 738.8% during the first quarter. Captrust Financial Advisors now owns 5,788 shares of the company’s stock worth $156,000 after acquiring an additional 5,098 shares during the period. Finally, BNP Paribas Arbitrage SA increased its position in TransMedics Group by 161.6% during the second quarter. BNP Paribas Arbitrage SA now owns 5,998 shares of the company’s stock worth $189,000 after acquiring an additional 3,705 shares during the period. Institutional investors own 88.58% of the company’s stock.

Insider Buying and Selling at TransMedics Group

In other news, Director David Weill sold 21,645 shares of the business’s stock in a transaction on Thursday, November 10th. The shares were sold at an average price of $56.00, for a total value of $1,212,120.00. Following the sale, the director now owns 13,500 shares in the company, valued at approximately $756,000. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other news, Director David Weill sold 21,645 shares of the business’s stock in a transaction on Thursday, November 10th. The shares were sold at an average price of $56.00, for a total value of $1,212,120.00. Following the sale, the director now owns 13,500 shares in the company, valued at approximately $756,000. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, VP John F. Carey sold 3,000 shares of the business’s stock in a transaction on Tuesday, November 1st. The shares were sold at an average price of $49.03, for a total transaction of $147,090.00. Following the completion of the sale, the vice president now owns 771 shares in the company, valued at approximately $37,802.13. The disclosure for this sale can be found here. Insiders have sold 116,373 shares of company stock valued at $6,904,458 in the last 90 days. 8.70% of the stock is currently owned by company insiders.

TransMedics Group Trading Down 2.9 %

Shares of TransMedics Group stock opened at $62.62 on Thursday. The firm has a market capitalization of $2.00 billion, a PE ratio of -41.75 and a beta of 1.57. The company has a debt-to-equity ratio of 0.31, a current ratio of 12.11 and a quick ratio of 11.21. The company’s fifty day moving average price is $58.96 and its two-hundred day moving average price is $49.39. TransMedics Group, Inc. has a 52-week low of $10.00 and a 52-week high of $65.47.

TransMedics Group (NASDAQ:TMDX – Get Rating) last announced its quarterly earnings results on Thursday, November 3rd. The company reported ($0.25) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.40) by $0.15. The firm had revenue of $25.68 million for the quarter, compared to analyst estimates of $18.96 million. TransMedics Group had a negative net margin of 58.78% and a negative return on equity of 46.03%. On average, analysts expect that TransMedics Group, Inc. will post -1.3 EPS for the current year.

Analysts Set New Price Targets

A number of equities analysts recently issued reports on the stock. Cowen boosted their target price on shares of TransMedics Group from $60.00 to $70.00 in a research report on Friday, December 16th. Canaccord Genuity Group boosted their target price on shares of TransMedics Group from $58.00 to $63.00 and gave the stock a “buy” rating in a research report on Friday, November 4th. Finally, Morgan Stanley boosted their target price on shares of TransMedics Group from $54.00 to $63.00 and gave the stock an “equal weight” rating in a research report on Friday, January 6th. One investment analyst has rated the stock with a hold rating and six have assigned a buy rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $53.29.

TransMedics Group Company Profile

(Get Rating)

TransMedics Group, Inc operates as a commercial stage medical technology company. The firm engages in the development and commercialization of organ care system platform. It focuses on the preservation of human organs for transplant in a near-physiologic condition to address the limitations of cold storage organ preservation.